STOCK TITAN

Mallinckrodt plc - MNK STOCK NEWS

Welcome to our dedicated page for Mallinckrodt plc news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on Mallinckrodt plc stock.

Mallinckrodt plc (MNK) is a global specialty biopharmaceutical and medical imaging company. Headquartered in Dublin, the company is renowned for developing, manufacturing, marketing, and distributing specialty pharmaceutical products and medical imaging agents. Its diverse portfolio spans therapeutic drugs for autoimmune and rare diseases in specialty areas such as neurology, rheumatology, nephrology, ophthalmology, and pulmonology. The company also focuses on immunotherapy, neonatal respiratory critical care therapies, analgesics, and central nervous system drugs.

The company's Specialty Brands segment features a range of branded medicines, while the Specialty Generics segment includes generic drugs and active pharmaceutical ingredients. The Global Medical Imaging segment provides contrast media and nuclear imaging agents. Mallinckrodt's expertise lies in the acquisition and management of highly regulated raw materials, regulatory know-how, and specialized chemistry, formulation, and manufacturing capabilities.

Recent achievements include findings from health economics outcomes research on Acthar® Gel, which were shared at the Academy of Managed Care Pharmacy Nexus 2023. Acthar Gel, approved by the FDA for treating various autoimmune disorders and inflammatory conditions, demonstrated cost-effectiveness for patients with advanced symptomatic sarcoidosis and nephrotic syndrome. Additionally, the company presented new data on TERLIVAZ® at the Society of Critical Care Medicine 2024 Critical Care Congress, showing its efficacy in improving kidney function in adults with hepatorenal syndrome.

Mallinckrodt is committed to continuous innovation, evidenced by the FDA's approval of the Acthar Gel Single-Dose Pre-filled SelfJect™ Injector, designed to provide patients with better control over their medication administration. Financially, Mallinckrodt reported a net sales increase to $467.8 million in Q1 2024, driven by growth in both its Specialty Brands and Specialty Generics segments.

Rhea-AI Summary

Mallinckrodt plc announced results from post-hoc studies of its investigational agent terlipressin for adults with hepatorenal syndrome type 1 (HRS-1). Presented at Kidney Week 2020, the analysis included data from three Phase 3 trials, showing that terlipressin significantly reduced the need for renal replacement therapy (RRT) compared to placebo. At Day 90, 29% of terlipressin patients needed RRT, compared to 45% on placebo. Additionally, RRT-free survival was higher in terlipressin patients at 90 days (37% vs. 29%). Terlipressin's safety and efficacy are still pending FDA approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Mallinckrodt has voluntarily initiated Chapter 11 bankruptcy proceedings in the U.S. to restructure its $1.3 billion debt and resolve overwhelming legal liabilities, particularly related to opioid claims. The company, along with its subsidiaries, will continue normal operations while implementing a restructuring support agreement (RSA) that aims to enhance its financial position and foster long-term growth. The RSA includes key stakeholders, and the company plans to address opioid claim settlements through a structured payment trust totaling $1.6 billion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Mallinckrodt plc (NYSE: MNK) announced that the FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) of terlipressin, intended to treat hepatorenal syndrome type 1 (HRS-1). The FDA stated that more data is needed to demonstrate a positive risk-benefit profile for terlipressin, which currently lacks FDA approval despite being used as standard care in other countries. HRS-1 affects 30,000 to 40,000 Americans annually, with a high mortality rate if untreated. Mallinckrodt remains committed to pursuing FDA approval, despite expressing disappointment with the CRL's issuance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Mallinckrodt Pharmaceuticals (NYSE: MNK) announced its Specialty Generics business received two Manufacturing Leadership Awards from the National Association of Manufacturers. The Hobart, N.Y. manufacturing site won awards in Operational Excellence Leadership for a packaging changeover project that cut time by 50%, and in Engineering and Production Technology Leadership for exceeding FDA serialization requirements. This is the third consecutive year of recognition, underscoring the company's commitment to quality manufacturing solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Mallinckrodt plc (NYSE: MNK) announced that the FDA accepted the Biologics License Application for StrataGraft skin tissue, an investigational therapy for adults with deep partial-thickness thermal burns. The FDA granted priority review, setting a PDUFA target date of February 2, 2021. The therapy aims to reduce the need for autografting, which is currently the standard care. Approximately 40,000 patients in the U.S. are hospitalized annually for severe burns. The development is supported by BARDA as part of a public health initiative.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

In Q2 2020, Mallinckrodt reported net sales of $166.5 million and adjusted net sales of $700.9 million, a 14.9% decline primarily due to COVID-19 impacts and competitive pressures. The diluted loss per share stood at $11.04, while adjusted diluted EPS was $1.89, down 25.3%. The company reported cash flow from operations of $170.9 million and free cash flow of $159.5 million. Additionally, they face potential Chapter 11 reorganization due to ongoing opioid litigation and high debt levels. Despite challenges, pipeline advancements include FDA advisory committee support for terlipressin.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Mallinckrodt plc (NYSE: MNK) announced that the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 8 to 7 in favor of recommending approval for terlipressin to treat hepatorenal syndrome type 1 (HRS-1), a severe condition linked to acute kidney failure in cirrhosis patients. There are currently no approved therapies for HRS-1 in the U.S., affecting 30,000 to 40,000 Americans annually. The FDA has set a PDUFA target date of September 12, 2020, for the New Drug Application review, following promising results from the Phase 3 CONFIRM trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Mallinckrodt (NYSE: MNK) is set to announce its second quarter 2020 earnings results on August 4, 2020, for the period ending June 26, 2020.

The conference call for investors will begin at 8:30 a.m. Eastern Time, with access available through their website, telephone, or audio replay. Investors can expect insights into the company's performance in areas like autoimmune and rare diseases, as well as specialty pharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

Mallinckrodt plc (NYSE: MNK) announced that the FDA's Cardiovascular and Renal Drugs Advisory Committee will hold a virtual meeting to review its New Drug Application (NDA) for terlipressin. This investigational drug targets hepatorenal syndrome type 1 (HRS-1), a severe condition with high mortality rates and no approved therapies in the U.S. The NDA is supported by data from the Phase 3 CONFIRM trial, the largest study of its kind for HRS-1, involving 300 patients. If approved, terlipressin could meet a critical medical need for approximately 30,000 to 40,000 annual patients in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Mallinckrodt plc (NYSE: MNK), a biopharmaceutical company, will present at the BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 8:00 a.m. Eastern Time. CEO Mark Trudeau and CFO Bryan Reasons will engage in a fireside chat during the event. Investors can access the webcast via the company's investor relations page. A replay will be available post-conference. Mallinckrodt specializes in treating autoimmune and rare diseases, focusing on various therapeutic areas. For more details, visit www.mallinckrodt.com/investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the market cap of Mallinckrodt plc (MNK)?

The market cap of Mallinckrodt plc (MNK) is approximately 4.5M.

What is Mallinckrodt's core business?

Mallinckrodt develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents, focusing on therapeutic drugs for autoimmune and rare diseases, immunotherapy, neonatal respiratory critical care therapies, and analgesics.

What recent achievements has Mallinckrodt made?

Recent achievements include health economics outcomes research on Acthar® Gel, showing its cost-effectiveness for certain conditions, and new data on TERLIVAZ® demonstrating its efficacy in improving kidney function in patients with hepatorenal syndrome.

What are the key segments of Mallinckrodt's business?

Mallinckrodt's business is divided into three key segments: Specialty Brands (branded medicines), Specialty Generics (generic drugs and active pharmaceutical ingredients), and Global Medical Imaging (contrast media and nuclear imaging agents).

What is Acthar® Gel?

Acthar® Gel is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides. It is approved by the FDA for treating several autoimmune disorders and inflammatory conditions.

What is TERLIVAZ® used for?

TERLIVAZ® (terlipressin) is used to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function, an acute and life-threatening condition.

What financial performance did Mallinckrodt report for Q1 2024?

Mallinckrodt reported net sales of $467.8 million for the first quarter of 2024, reflecting a 10.2% increase compared to the same period in 2023.

What new product did Mallinckrodt recently launch?

Mallinckrodt recently launched the Acthar® Gel Single-Dose Pre-filled SelfJect™ Injector, designed to provide patients with better control over their medication administration.

How does Mallinckrodt support patients using Acthar® Gel?

Mallinckrodt offers a suite of support services for eligible Acthar® Gel patients, including insurance coverage assistance, commercial copay assistance, a patient assistance program, injection training services, and nurse navigator support.

What is the significance of Mallinckrodt's specialty generics segment?

Mallinckrodt's Specialty Generics segment includes high-quality generic drugs and active pharmaceutical ingredients, serving a critical role in the market by ensuring a stable supply of essential medicines amidst ongoing shortages and supply chain constraints.

Where can investors find more information about Mallinckrodt?

Investors can find more information on Mallinckrodt's website, particularly in the Investor Relations section, which provides updates on company performance, press releases, and financial information.

Mallinckrodt plc

NYSE:MNK

MNK Rankings

MNK Stock Data

4.52M
5.72M
10.09%
96.64%
13.46%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Ireland
Dublin